drugset / Trial / NCT00233506
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
Phase 1
Completed
41 enrolled
University of Iowa
Mayo Clinic · collabNational Cancer Institute (NCI) · collabPfizer · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
* CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG
Timeline
- Start
- 2004-07
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agatolimod | Oligonucleotide (other) | — | Intravenous |